JNJ-67571244 is a bispecific antibody that targets CD3, which is expressed on T-cells and CD33, which is frequently expressed in acute myeloma leukemia (AML) and myelodysplastic syndrome (MDS). JNJ-67571244 was created under a collaboration between Genmab and Janssen Biotech, Inc.  using Genmab’s DuoBody® technology.

Clinical studies
JNJ-67571244 is being investigated in a Phase I clinical study to treat relapsed or refractory AML or MDS.